List of Zecuity drug patents

Zecuity is owned by Teva Branded Pharm.

Zecuity contains Sumatriptan Succinate.

Zecuity has a total of 10 drug patents out of which 0 drug patents have expired.

Zecuity was authorised for market use on 17 January, 2013.

Zecuity is available in system;iontophoresis dosage forms.

Zecuity can be used as method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation.

The generics of Zecuity are possible to be released after 08 October, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6745071 TEVA BRANDED PHARM Iontophoretic drug delivery system
Feb, 2023

(15 days from now)

US8155737 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(4 years from now)

US8470853 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(4 years from now)

US7973058 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(4 years from now)

US9427578 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(4 years from now)

US8597272 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(4 years from now)

US9272137 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Sep, 2027

(4 years from now)

US8366600 TEVA BRANDED PHARM Polyamine enhanced formulations for triptan compound iontophoresis
Apr, 2029

(6 years from now)

US8983594 TEVA BRANDED PHARM Electronic control of drug delivery system
Nov, 2030

(7 years from now)

US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system
Oct, 2032

(9 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 17 January, 2013

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation

Dosage: SYSTEM;IONTOPHORESIS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic